Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 123

Similar articles for PubMed (Select 9713134)

1.

An evaluation of clinical, serologic, anatomopathologic and immunohistochemical findings for fifteen patients with mucosal leishmaniasis before and after treatment.

Amato VS, Duarte MI, Nicodemo AC, de Carvalho LV, Pagliari C, da Matta VL, de Oliveira LS, de Castro SM, Uip DE, Amato JG, Amato Neto V.

Rev Inst Med Trop Sao Paulo. 1998 Jan-Feb;40(1):23-30.

PMID:
9713134
2.

Mucocutaneous leishmaniasis: mucosal manifestations in an endemic country.

de Paulo LF, Rocha GF, Luisi CM Jr, Rosa RR, Durighetto AF Jr.

Int J Infect Dis. 2013 Nov;17(11):e1088-9. doi: 10.1016/j.ijid.2013.05.013. Epub 2013 Jul 16. No abstract available.

3.

Efficacy of extended (six weeks) treatment with miltefosine for mucosal leishmaniasis in Bolivia.

Soto J, Rea J, Valderrama M, Toledo J, Valda L, Ardiles J, Berman J.

Am J Trop Med Hyg. 2009 Sep;81(3):387-9.

4.

[Mucosal leishmaniasis by contiguity with a skin lesion: another case report from Tunisia].

El Fékih N, Sliti N, Kharfi M, Trabelsi S, Khaled S, Fazaa B, Kamoun MR.

Med Trop (Mars). 2008 Dec;68(6):634-6. French.

PMID:
19639835
5.

Alterations in phenotypic profiles of peripheral blood cells from patients with human American cutaneous leishmaniasis following treatment with an antimonial drug and a vaccine.

Botelho AC, Mayrink W, Oliveira RC.

Acta Trop. 2009 Nov;112(2):143-8. doi: 10.1016/j.actatropica.2009.07.012. Epub 2009 Jul 22.

PMID:
19631187
6.

Drug hypersensitivity syndrome induced by meglumine antimoniate.

Jeddi F, Caumes E, Thellier M, Jauréguiberry S, Mazier D, Buffet PA.

Am J Trop Med Hyg. 2009 Jun;80(6):939-40.

7.

Mucosal leishmaniasis: description of case management approaches and analysis of risk factors for treatment failure in a cohort of 140 patients in Brazil.

Amato VS, Tuon FF, Imamura R, Abegão de Camargo R, Duarte MI, Neto VA.

J Eur Acad Dermatol Venereol. 2009 Sep;23(9):1026-34. doi: 10.1111/j.1468-3083.2009.03238.x. Epub 2009 May 4.

PMID:
19453817
8.

Cutaneous and mucocutaneous leishmaniasis in Tigray, northern Ethiopia: clinical aspects and therapeutic concerns.

Padovese V, Terranova M, Toma L, Barnabas GA, Morrone A.

Trans R Soc Trop Med Hyg. 2009 Jul;103(7):707-11. doi: 10.1016/j.trstmh.2009.02.023. Epub 2009 Apr 7.

PMID:
19356780
9.

A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis.

Nilforoushzadeh MA, Jaffary F, Ansari N, Siadat AH, Nilforoushan Z, Firouz A.

J Vector Borne Dis. 2008 Dec;45(4):287-91.

10.

Efficacy of cryotherapy versus intralesional meglumine antimoniate (glucantime) for treatment of cutaneous leishmaniasis in children.

Layegh P, Pezeshkpoor F, Soruri AH, Naviafar P, Moghiman T.

Am J Trop Med Hyg. 2009 Feb;80(2):172-5.

11.

Cutaneous leishmaniasis with boggy induration and simultaneous mucosal disease.

Mings S, Beck JC, Davidson C, Ondo AL, Shanler SD, Berman J.

Am J Trop Med Hyg. 2009 Jan;80(1):3-5.

12.

Drug regimens for visceral leishmaniasis in Mediterranean countries.

Gradoni L, Soteriadou K, Louzir H, Dakkak A, Toz SO, Jaffe C, Dedet JP, Campino L, Cañavate C, Dujardin JC.

Trop Med Int Health. 2008 Oct;13(10):1272-6. doi: 10.1111/j.1365-3156.2008.02144.x. Epub 2008 Aug 24.

13.

Failure of both azithromycin and antimony to treat cutaneous leishmaniasis in Manaus, AM, Brazil.

Teixeira AC, Paes MG, Guerra Jde O, Prata A, Silva-Vergara ML.

Rev Inst Med Trop Sao Paulo. 2008 May-Jun;50(3):157-60.

14.

Mutilating lupoid leishmaniasis: twelve years to make the diagnosis!

Ghosn S, Dahdah MJ, Kibbi AG.

Dermatology. 2008;216(2):187-9. doi: 10.1159/000113292. Epub 2008 Jan 23. No abstract available.

PMID:
18216488
15.

Mucosal leishmaniasis . Current scenario and prospects for treatment.

Amato VS, Tuon FF, Bacha HA, Neto VA, Nicodemo AC.

Acta Trop. 2008 Jan;105(1):1-9. Epub 2007 Aug 19. Review.

PMID:
17884002
16.

[Clinical and histological study of lupoid cutaneous leishmaniasis (16 cases)].

Masmoudi A, Boudaya S, Ayadi N, Bouassida S, Khabir A, Meziou TJ, Akrout F, Sallemi T, Turki H, Zahaf A.

Presse Med. 2007 Dec;36(12 Pt 1):1738-42. Epub 2007 Sep 6. French.

PMID:
17825519
17.

Treatment of mucosal leishmaniasis in Latin America: systematic review.

Amato VS, Tuon FF, Siqueira AM, Nicodemo AC, Neto VA.

Am J Trop Med Hyg. 2007 Aug;77(2):266-74. Review.

19.

Can interferon-gamma and interleukin-10 balance be associated with severity of human Leishmania (Viannia) braziliensis infection?

Gomes-Silva A, de Cássia Bittar R, Dos Santos Nogueira R, Amato VS, da Silva Mattos M, Oliveira-Neto MP, Coutinho SG, Da-Cruz AM.

Clin Exp Immunol. 2007 Sep;149(3):440-4. Epub 2007 Jul 5.

20.

Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran.

Mohebali M, Fotouhi A, Hooshmand B, Zarei Z, Akhoundi B, Rahnema A, Razaghian AR, Kabir MJ, Nadim A.

Acta Trop. 2007 Jul;103(1):33-40. Epub 2007 May 18.

PMID:
17586452
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk